Levofolinic Acid Medac

Levoleucovorin disodium, the active ingredient in Levofolinic Acid Medac, is a folate analog presented as an injectable solution for intravenous use. It provides reduced folate to protect normal cells during antifolate chemotherapy such as methotrexate and 5‑fluorouracil. GNH USA supplies Levofolinic Acid Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Levofolinic Acid Medac is used in oncology to mitigate the toxic effects of antifolate chemotherapy agents. - High‑dose methotrexate rescue: reduces systemic toxicity and supports rapid recovery of normal tissue. - 5‑Fluorouracil adjunct: enhances the therapeutic window by protecting healthy cells. - General leucovorin rescue in cancer treatment: supplies reduced folate to maintain DNA synthesis in non‑cancerous cells.

Levofolinic Acid Medac is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea or vomiting - Mild skin rash or erythema - Transient elevation of liver enzymes - Low‑grade fever - Flushing or warmth at the infusion site - Mild headache

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Acute renal impairment - Severe hypotension or shock - Pulmonary edema or respiratory distress - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Cardiac arrhythmias or myocardial ischemia

Levofolinic Acid Medac should be administered with careful clinical monitoring. - Renal function: assess baseline creatinine and monitor during therapy. - Hepatic function: check liver enzymes before and after infusion. - Hypersensitivity: discontinue immediately if signs of severe allergic reaction appear. - Concomitant methotrexate: coordinate timing to ensure effective rescue and avoid overlapping toxicity. - Pregnancy: use only when the potential benefit justifies the potential risk to the fetus. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levofolinic Acid Medac may interact with several agents used in cancer regimens.

Major Interactions (Avoid): - Methotrexate: concurrent high‑dose may diminish rescue effectiveness. - 5‑Fluorouracil: timing must be coordinated to prevent antagonism. - Cytarabine: combined use may increase cytotoxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: can affect renal clearance of the drug. - Aminoglycosides: may heighten risk of nephrotoxicity. - Loop diuretics: may alter electrolyte balance and renal handling.